Early-stage research into next-generation obesity therapies and their implications for treatment durability and clinical priorities. A clear-eyed industry analysis you'll want to read.
Key Takeaways
- Combination with semaglutide produced deeper weight loss and increased muscle and endurance
- MS 001 increased energy expenditure and fat metabolism without reducing food intake
- Animals treated with MS 001 experienced less weight regain after GLP-1 discontinuation